Results 121 to 130 of about 25,471 (263)
Postmarketing surveillance of adverse reactions to drugs [PDF]
, 1984 E. S. Snell
openalex +1 more source
Postmarketing Surveillance of Zopiclone in Insomnia: Analysis of 20,513 Cases [PDF]
, 1991 H. Allain +5 more
openalex +1 more source
Basic Emollients for Xerosis Cutis in Atopic Dermatitis: A Review of Clinical Studies
International Journal of Dermatology, Volume 64, Issue S1, Page 13-28, June 2025.ABSTRACT Xerosis cutis (dry skin) is a common and burdensome symptom of atopic dermatitis (AD). Topical emollients restore skin hydration and barrier function through the physicochemical properties of their nonactive constituents (e.g., glycerol, urea, lactic acid, liquid paraffin, petrolatum) and represent the mainstay of basic therapy for xerosis ...
Andreas Wollenberg +2 more
wiley +1 more source
Vascular Health and Risk Management, 2013 Yasufumi Kuroda,1 Chie Hirayama,2 Hitoshi Hotoda,2 Yasuhiro Nishikawa,2 Akinori Nishiwaki21Daiichi Sankyo Pharma Development, Edison, NJ, USA; 2Daiichi Sankyo Company, Limited, Tokyo, JapanPurpose: Edoxaban is an oral, once-daily, selective, direct ...
Kuroda Y +4 more
doaj
The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
Therapeutic Advances in Neurological Disorders, 2017 Natalizumab, a monoclonal antibody that blocks lymphocyte infiltration in the central nervous system, is a valuable tool in the treatment of relapsing forms of multiple sclerosis (MS). In a phase III clinical trial comparing natalizumab with placebo over
Barry A. Singer
doaj +1 more source
Natural History of Idiosyncratic Drug‐Induced Liver Injury and Prognostic Models
Liver International, Volume 45, Issue 6, June 2025.ABSTRACT Background and Aims: Drug‐induced liver injury (DILI) remains a leading cause of acute liver failure worldwide. Drugs such as isoniazid, alone or in combination with other anti‐tuberculosis drugs, as well as a growing number of herbal and complementary medicines, have been implicated in most cases of acute liver failure in registry studies ...
Harshad C. Devarbhavi, Raúl J. Andrade
wiley +1 more source
JAMA Network Open, 2019 This cross-sectional study characterizes postapproval clinical trials sponsored by pharmaceutical companies of therapeutics approved by the US Food and Drug Administration (FDA) without postmarketing requirements or commitments.
Joshua J. Skydel +4 more
semanticscholar +1 more source
Clinical efficacy and safety of alemtuzumab in postmarketing practice
Медицинский совет, 2019 Clinical trials confirm alemtuzumab efficacy for multiple sclerosis treatment in terms of both conventional measures and combined criteria such as NEDA (no evidence of disease activity).
N. V. Khachanova
doaj +1 more source